

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy

S Franceschi^{*1}, L Dal Maso², M Rickenbach³, J Polesel², B Hirschel⁴, M Cavassini⁵, A Bordoni⁶, L Elzi⁷, S Ess⁸, G Jundt⁹, N Mueller¹⁰, GM Clifford¹ and the Swiss HIV Cohort Study¹¹

¹International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France; ²Epidemiology and Biostatistics Unit, Aviano Cancer Center, Via Franco Gallini 2, 33081 Aviano, Italy; ³Coordination and Data Center, Swiss HIV Cohort Study, Mont-Paisible 16, CHUV, 1011 Lausanne, Switzerland; ⁴Division of Infectious Diseases, Department of Internal Medicine, University Hospital of Geneva, Rue Michel-du-Crest 24, CH-1211 Geneva 14, Switzerland; ⁵Division of Infectious Diseases, Department of Medicine 2, CHUV Lausanne, Lausanne 1011, Switzerland; ⁶Cancer Registry of the Canton of Ticino, Via in Selva 24, CH-6600 Locarno, Switzerland; ⁷Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland; ⁸Cancer Registry of St Gallen and Appenzell, PO Box 2, CH-9007 St Gallen, Switzerland; ⁹Cancer Registry of Basel, Schönbeinstrasse 40, CH-4003 Basel, Switzerland; ¹⁰Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland

Between 1984 and 2006, 12 959 people with HIV/AIDS (PWHA) in the Swiss HIV Cohort Study contributed a total of 73 412 person-years (py) of follow-up, 35 551 of which derived from PWHA treated with highly active antiretroviral therapy (HAART). Five hundred and ninety-seven incident Kaposi sarcoma (KS) cases were identified of whom 52 were among HAART users. Cox regression was used to estimate hazard ratios (HR) and corresponding 95% confidence intervals (CI). Kaposi sarcoma incidence fell abruptly in 1996–1998 to reach a plateau at 1.4 per 1000 py afterwards. Men having sex with men and birth in Africa or the Middle East were associated with KS in both non-users and users of HAART but the risk pattern by CD4 cell count differed. Only very low CD4 cell count (<50 cells μl^{-1}) at enrolment or at HAART initiation were significantly associated with KS among HAART users. The HR for KS declined steeply in the first months after HAART initiation and continued to be low 7–10 years afterwards (HR, 0.06; 95% CI, 0.02–0.17). Thirty-three out of 52 (63.5%) KS cases among HAART users arose among PWHA who had stopped treatment or used HAART for less than 6 months.

British Journal of Cancer (2008) 99, 800–804. doi:10.1038/sj.bjc.6604520 www.bjcancer.com

Published online 29 July 2008

© 2008 Cancer Research UK

Keywords: HIV; AIDS; Kaposi sarcoma; antiretroviral drugs; Swiss HIV cohort study

At the beginning of the HIV epidemic, Kaposi sarcoma (KS) was one of the most common manifestations of AIDS (Dal Maso *et al*, 1995; Biggar *et al*, 1996), present during the mid-1980s in 25% of individuals at the time of AIDS diagnosis in the United States, but decreased steadily through the late 1980s and mid-1990s, down to 2% after the advent and widespread use of highly active antiretroviral therapy (HAART) in 1996 (Engels *et al*, 2006).

A similar temporal pattern was observed for KS in Australia (Grulich *et al*, 2001) and in European countries (Dal Maso *et al*, 1995; Rezza *et al*, 2000; Franceschi *et al*, 2003; Mocroft *et al*, 2004; Clifford *et al*, 2005), but detailed data on the long-term trends of KS incidence in Europe are limited. We therefore took advantage of the more than 20 years of follow-up data available from the Swiss HIV Cohort Study (SHCS) to assess changes in the incidence of and risk factors for KS before and after HAART use.

*Correspondence: Dr S Franceschi; E-mail: franceschi@iarc.fr

¹¹The members of the Swiss HIV Cohort Study are M Battegay, E Bernasconi, J Böni, HC Bucher, Ph Bürgisser, A Calmy, S Cattacin, M Cavassini, R Dubs, M Egger, L Elzi, M Fischer, M Flepp, A Fontana, P Francioli (President of the SHCS, Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne), H Furrer (Chairman of the Clinical and Laboratory Committee), C Fux, M Gorgievski, H Günthard (Chairman of the Scientific Board), H Hirsch, B Hirschel, I Hösli, Ch Kahlert, L Kaiser, U Karrer, C Kind, Th Klimkait, B Ledergerber, G Martinetti, B Martinez, N Müller, D Nadal, M Opravil, F Paccaud, G Pantaleo, A Rauch, S Regenass, M Rickenbach (Head of Data Center), C Rudin (Chairman of the Mother & Child Substudy), P Schmid, D Schultze, J Schüpbach, R Speck, P Taffé, A Telenti, A Trkola, P Vernazza, R Weber, S Yerly
Received 14 May 2008; revised 23 June 2008; accepted 25 June 2008; published online 29 July 2008

MATERIALS AND METHODS

The SHCS is an ongoing study that has been enrolling people with HIV/AIDS (PWHA) over 16 years of age since 1988, with some retrospective enrolment going back to 1984, from seven large hospitals in Swiss cities (Basel, Bern, Geneva, Lausanne, Lugano, St Gallen, and Zurich) (www.shcs.ch). Follow-up visits take place every 6 months and all AIDS-defining events, including KS diagnosis and death, are recorded. The present study included PWHA enrolled up to 30 September 2005, and information recorded in the SHCS database up to 31 March 2006. People with HIV/AIDS were excluded from the present study if they (1) did not have information on date of birth, gender, or HIV transmission category (number (n) = 54), (2) were diagnosed with KS at

enrolment or earlier ($n=368$), or (3) had no follow-up visits ($n=131$).

A total of 597 KS cases were included in our present study: 545 were identified from the SHCS database, and 52 through record linkage with eight Swiss Cantonal Cancer Registries (Clifford *et al*, 2005). Six of these cancer registries (Basel, Geneva, Ticino, St Gallen and Appenzell, Vaud, and Zurich) overlap directly with six of the seven cantons covered by SHCS hospitals (all except Bern). The Neuchâtel and Valais Cancer Registries do not directly overlap with SHCS hospitals, but some residents of these cantons are followed in a neighbouring SHCS hospital. Places of birth were classified as Europe (Switzerland and the rest of Europe, 87.1% of PWHA) and Africa or the Middle East (8.1%). The few SHCS participants born outside Europe, but in countries where KS is not endemic (e.g., the Americas and Asia; Hengge *et al*, 2002), were included in the Europe category. Conversely, the few PWHA born in the Caribbean were included in the Africa/Middle East category. Histological confirmation was mentioned in the majority of KS cases, but presentation site (i.e., skin only vs other) was available only for 382 (64%) KS cases.

Highly active antiretroviral therapy was defined as a combination of at least three drugs, including a protease inhibitor or a non-nucleoside transcriptase inhibitor, or three nucleosides including abacavir. Individuals who had used HAART for more than 1 month were classified as users. Treatment interruption was defined as in a previous report from the SHCS (Taffé *et al*, 2002), as absence of any antiretroviral drug in PWHA who were previously receiving HAART. Taffé *et al* (2002) evaluated the impact of interruptions of less than 3 months on the progression of HIV infection, whereas we focused on the impact of interruptions of 3 months or more on KS incidence. CD4 cell counts at enrolment in the SHCS and, among HAART users, at, or within 6 months before HAART initiation were retrieved.

For each participant, person-years (py) at risk were calculated between enrolment and KS diagnosis, death, or last follow-up visit, whichever occurred first. Incidence rates per 1000 py were standardised for gender and age based on the enrolled population in the overall study period, using the direct method (Breslow and Day, 1987). Ninety-five percent confidence intervals (CI) of incidence were computed according to the Poisson distribution (Breslow and Day, 1987). The effect of various risk factors on KS onset was assessed using hazard ratios (HR) and corresponding 95% CI, estimated by means of the Cox proportional hazard model (Cox, 1972), and adjusted for SHCS centre, gender, age (in 5-year groups), HIV transmission category (MSM and non-MSM) and, when mentioned, CD4 cell count at enrolment or at HAART initiation (<50, 50–99, 100–199, 200–349, ≥ 350 cells μl^{-1} , and unknown). Calendar period, HAART use, and months after HAART initiation and after treatment interruption were introduced as time-dependent variables.

This study was approved by the local ethics committees of the collaborating SHCS clinics and of the International Agency for Research on Cancer.

RESULTS

The present study included 12 638 PWHA who were KS-free at enrolment and among whom 597 incident KS cases were identified (8.2 per 1000 py; 95% CI, 7.6–8.9). Fifteen per cent of PWHA had AIDS at enrolment and an additional 3119 (24.7%) developed it during follow-up. Among the latter, KS was the AIDS-defining illness in 268, whereas 329 KS cases developed in PWHA who had already manifested another AIDS-defining illness.

Figure 1 shows KS temporal trends: overall KS incidence was 33.3 per 1000 py in 1984–1986 and did not change significantly in the subsequent periods until 1996–1998, when it fell to 5.1 (95% CI, 3.9–6.5) per 1000 py. Kaposi sarcoma incidence further




Figure 1 Incidence rates of KS by calendar period, overall and according to HIV transmission category. Rates were standardised (direct method) on age and gender, based on Swiss HIV Cohort Study participants. Vertical bars represent 95% CI. MSM: men having sex with men.

decreased to 1.4 per 1000 py in 1999–2001 and remained constant thereafter. Temporal trends in KS incidence were chiefly driven by men having sex with men (MSM), but they were consistent among other HIV transmission categories (Figure 1).

A large proportion (48.4%) of available py derived from HAART users and Table 1 shows the incidence and HR of KS by various characteristics separately among non-users and users of HAART. Incidence of KS decreased from 15.0 per 1000 py in non-users to 1.3 per 1000 py in users (HR, 0.11; 95% CI, 0.08–0.14). Among non-users of HAART, intravenous drug users (HR, 0.09; 95% CI, 0.06–0.13), and heterosexuals and other HIV transmission categories (HR, 0.27; 95% CI, 0.20–0.36) showed a lower KS incidence than MSM. The HR for KS was increased among PWHA older than 35 years (HR, 1.53; 95% CI, 1.29–1.82) and those born in Africa/Middle East (HR, 1.84; 95% CI, 1.10–3.06). Kaposi sarcoma risks among non-users of HAART steeply increased with decreasing CD4 cell count (HR for <50 vs ≥ 350 cells μl^{-1} , 12.85; 95% CI, 9.59–17.23). These associations were also present, but were weaker, among HAART users with the exception of the association with place of birth that became stronger (HR for Africa/Middle East vs Europe among HAART users, 6.49; 95% CI, 2.79–15.11). In contrast with non-users, no change in the HR for KS was seen among HAART users with CD4 cell counts in the range of 50– ≥ 350 cells μl^{-1} and the only significant risk increase was found for CD4 cell count less than 50 cells μl^{-1} at enrolment (HR, 3.26; 95% CI, 1.53–6.91). On account of the rarity of KS among HAART users, HRs showed, however, broad CIs (Table 1).

Among HAART users, CD4 cell count at treatment initiation below 50 cells μl^{-1} (HR vs ≥ 350 cells μl^{-1} , 5.36; 95% CI, 2.08–13.80) (data not shown) was even more strongly associated with KS risk than CD4 cell count at enrolment. Furthermore, KS risk was greatly increased among PWHA who had stopped using any antiretroviral drugs for at least 3 months (HR, 8.14; 95% CI, 4.01–16.54) (Table 1). Additional adjustment for CD4 cell count at HAART initiation did not modify the HR for treatment interruption (HR, 9.45; 95% CI, 4.64–19.25, data not shown).

Skin was reported as the presentation site in the majority of KS cases (74.3%). Temporal trends and associations with HAART use and CD4 cell count (overall and in separate strata by HAART use) did not differ by KS presentation site (data not shown).

Figure 2 shows the HR for KS in different periods after HAART initiation compared with non-users. The HR of KS was already reduced by 76% in the first 5 months of use and declined to 0.06 (95% CI, 0.02–0.17) in the subsequent 6 months of use. The

Table 1 Incidence rates and HR of KS overall and by selected characteristics, and use of HAART

	HAART non-users ^a				HAART users			
	KS	py	Incidence/1000 py (95% CI) ^b	HR (95% CI) ^c	KS	py	Incidence/1000 py (95% CI) ^b	HR (95% CI) ^c
Overall	545	37 861	15.0 (13.8–16.3)	1 ^d	52	35 551	1.3 (1.0–1.7)	0.11 (0.08–0.14)
<i>HIV transmission category</i>								
MSM ^d	446	10 900	27.8 (25.3–30.5)	1	35	12 216	1.6 (1.1–2.3)	1
Het/Oth	62	10 183	8.9 (6.8–11.4)	0.27 (0.20–0.36)	16	13 796	1.2 (0.7–1.9)	0.54 (0.27–1.10)
IDU	37	16 778	2.1 (1.5–2.9)	0.09 (0.06–0.13)	1	9 539	0.0 (0.0–0.3)	0.05 (0.01–0.37)
<i>Age at enrolment (years)</i>								
< 35 ^d	256	27 795	7.4 (6.5–8.4)	1	25	20 136	0.9 (0.6–1.3)	1
≥ 35	289	10 066	17.6 (15.7–19.8)	1.53 (1.29–1.82)	27	15 416	1.4 (1.0–2.1)	1.07 (0.61–1.85)
<i>Place of birth</i>								
Europe ^d	529	36 334	15.0 (13.8–16.4)	1	43	32 495	1.0 (0.7–1.4)	1
Africa/Middle East	16	1 527	12.5 (7.1–20.4)	1.84 (1.10–3.06)	9	3 057	2.4 (1.1–4.6)	6.49 (2.79–15.11)
<i>CD4 cell count at enrolment (cells μl⁻¹)</i>								
≥ 350 ^d	128	20 988	6.7 (5.6–8.0)	1	18	15 212	1.0 (0.6–1.6)	1
200–349	93	6 126	15.3 (12.4–18.8)	2.44 (1.86–3.20)	9	8 382	0.9 (0.4–1.8)	0.84 (0.38–1.88)
50–199	133	3 883	33.6 (28.2–39.9)	5.04 (3.90–6.51)	11	7 556	1.1 (0.6–2.0)	1.13 (0.53–2.44)
< 50	94	1 119	77.1 (62.3–94.3)	12.85 (9.59–17.23)	12	3 021	4.8 (2.5–8.4)	3.26 (1.53–6.91)
Unknown	97	5 745	18.1 (14.7–22.1)	—	2	1 381	0.7 (0.1–2.7)	—
<i>Treatment interruption^e</i>								
No ^d	—	—	—	—	28	27 234	0.9 (0.6–1.2)	1
Yes	—	—	—	—	24	8 317	2.8 (1.8–4.1)	8.14 (4.01–16.54)

CI = confidence interval; HAART = highly active antiretroviral therapy; Het/Oth = heterosexuals and other; HR = hazard ratio; IDU = intravenous drug users; KS = Kaposi sarcoma; MSM = men having sex with men; py = person-years. ^aIndividuals who were never treated with HAART and py before HAART among HAART users. ^bRates are standardised (direct method) on age and/or gender based on all SHCS participants. ^cAdjusted for centre, age, gender, and HIV transmission category, when appropriate. ^dReference category. ^eAbsence of any antiretroviral drug for ≥ 3 months.




Figure 2 Hazard ratio of Kaposi sarcoma in patients receiving highly active antiretroviral therapy (HAART) following treatment initiation. Adjusted for centre, age, gender, HIV transmission category (men having sex with men, other), and CD4 cell count at enrolment. Vertical bars represent 95% confidence intervals. Reference category was defined as non-users of HAART.

reduction in KS risk persisted unchanged up to 84–119 months after HAART initiation (HR, 0.06; 95% CI, 0.02–0.16) (Figure 2).

Finally, the 52 HAART users who developed KS were individually reviewed and classified into the following groups: (1) no antiretroviral drug in the 3 months before KS diagnosis; (2) recent initiation of HAART (< 6 months before KS diagnosis); (3) severe immunodeficiency (CD4 cell count < 100 cells μl⁻¹ at KS onset while on HAART for ≥ 6 months); and (4) none of the above

(data not shown). Eighteen (34.6%) KS cases had not been taking any antiretroviral drug for 3 months or more, and in 10 instances for 12 months or longer. Recent initiation of HAART was identified in 15 KS cases, among whom five of the nine KS were from Africa/Middle East. Severe immunodeficiency was identified among 10 KS cases. Nine KS cases, all from the MSM transmission category, could not be assigned to any of the three categories above. Five of them (aged 35, 49, 52, 56, and 63 years) had a CD4 cell count ≥ 400 cells μl⁻¹ (i.e., 405, 440, 557, 596, 782) at KS diagnosis.

DISCUSSION

Our study shows the dramatic decline of KS incidence in the SHCS following the advent of HAART. This expands an earlier report (Ledergerber *et al*, 1999) from this cohort showing that by 1998 the KS decline was at least as large as that seen for opportunistic infections. Similar reductions in the incidence of KS among PWHA were seen in many other studies (International Collaboration on HIV and Cancer, 2000) although the decrease started earlier (i.e., even before the introduction of HAART) in the United States (Biggar *et al*, 1996; Engels *et al*, 2006) and Australia (Grulich *et al*, 2001) than in Europe (Dal Maso *et al*, 1995). The prevalence of KS herpesvirus, the cause of KS (IARC, 1997), may have been especially high in the first wave of HIV infection in MSM in the United States and Australia (Osmond *et al*, 2002).

Highly active antiretroviral therapy became rapidly available to SHCS participants and, by 1997, 80% of them were using three antiretroviral drugs or more (www.shcs.ch). The proportion of SHCS participants with CD4 cell counts < 350 cells μl⁻¹ who had never been treated was small (< 3%) in 2006 in all HIV transmission categories. Despite the widespread use of HAART and the introduction after 1996 of successively more potent

antiretroviral drugs, KS incidence in the SHCS seems to have reached a plateau after 2001, as reported among AIDS patients in the United States (Engels *et al*, 2006).

In addition to making KS a relatively rare event, HAART use has also diminished the variation in KS risk by host characteristics, including gender, age group, and to some extent, HIV transmission category and CD4 cell count at enrolment as compared with that found among non-users. Only a count <50 cells μl^{-1} at enrolment or HAART initiation was associated with an increased HR for KS. Reduced importance of CD4 cell count at enrolment in HAART users *vs* non-users was also seen in the SHCS for non-Hodgkin's lymphoma, but the impact of HAART on non-Hodgkin's lymphoma was weaker (HR, 0.26; 95% CI, 0.20–0.33) than on KS, and, hence, non-Hodgkin's lymphoma incidence (1.9; 95% CI, 1.6–2.6 per 1000 py) became higher than KS incidence among HAART users (Polesel *et al*, 2008).

Kaposi sarcoma risk was already reduced by over 90% after 1 year of HAART and it did not show any sign of increasing again for at least 10 years. The decline of non-Hodgkin's lymphoma risk after HAART initiation was more gradual than for KS, but equally prolonged (Polesel *et al*, 2008).

Approximately one-third of HAART users in the SHCS had one or more interruptions of antiretroviral treatment (Taffé *et al*, 2002) due in most cases either to intolerance to drugs, or social factors (i.e., being an intravenous drug user, poor education, etc.), and not to treatment failure. In our study, the absence of any antiretroviral treatment for 3 months or more was associated with an eight-fold increased KS risk, thus confirming the danger of treatment interruption already reported with respect to progression to AIDS or death (Holkmann *et al*, 2007). Significantly higher KS incidence among PWHA who were assigned to the CD4 cell-guided intermittent antiretroviral treatment arm than those assigned to the continuous treatment arm was also shown in a randomised clinical trial (Silverberg *et al*, 2007).

Of the 52 KS among HAART users, 23 arose among people who had either stopped using HAART at or had initiated treatment less than 6 months before KS diagnosis. Recent initiation of HAART in the SHCS seemed especially important among KS cases born in Africa/Middle East, suggesting possible delays in the diagnosis or

treatment of HIV infection. Ten KS cases arose in PWHA whose CD4 cell count was very low despite concurrent HAART use whereas 5 MSM developed KS despite being on HAART and having CD4 cell counts at which AIDS-related KS is seldom seen (Biggar *et al*, 2007). The occurrence of KS cases in PWHA with high CD4 cell counts and undetectable viral loads has already been reported in the United States after 1996 (Maurer *et al*, 2007; Krown *et al*, 2008). It is possible that, with the ageing of PWHA, those who are co-infected with KS herpesvirus may develop KS despite good control of HIV infection.

Weaknesses of our study are the lack of information on year of HIV seroconversion and on the presence of KS herpesvirus co-infection. Furthermore, we evaluated HAART use by intention-to-treat, that is, without subtracting all periods where treatment had been stopped, so its efficacy may be underestimated. A major strength of our cohort study is that it is the largest ever reported with respect to the number of KS cases and the number of person-years of HAART use. Furthermore, the representativeness of the SHCS with respect to Swiss PWHA was especially good (i.e., inclusion of 49% of all HIV-positive people and 67% of all AIDS cases in the country, www.shcs.ch).

ACKNOWLEDGEMENTS

This study was performed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation, and was funded by a grant from OncoSuisse (ICP OCS 01355-03-2003) and the Istituto Superiore di Sanità, Rome, Italy (Grant 20 G.3). We thank the staff of the Swiss Cantonal Cancer Registries, especially C Bouchardy (Geneva), D De Weck (Valais), N Probst-Hensch (Zurich), and F Levi (Vaud and Neuchâtel) for help with identification of KS cases and T Perdrix-Thoma for technical assistance.

Conflict of interest

The authors declare no conflict of interest.

REFERENCES

- Biggar RJ, Chaturvedi AK, Goedert JJ, Engels EA (2007) AIDS-related cancer and severity of immunosuppression in persons with AIDS. *J Natl Cancer Inst* **99**: 962–972
- Biggar RJ, Rosenberg PS, Cote T (1996) Kaposi's sarcoma and non-Hodgkin's lymphoma following the diagnosis of AIDS. Multistate AIDS/Cancer Match Study Group. *Int J Cancer* **68**: 754–758
- Breslow NE, Day NE (1987) *Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies* IARC Scientific Publications No. 82 International Agency for Research on Cancer: Lyon
- Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S (2005) Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. *J Natl Cancer Inst* **97**: 425–432
- Cox DR (1972) Regression models and life-time tables. *J R Stat Soc B* **34**: 187–220
- Dal Maso L, Franceschi S, Negri E, Serraino D, La Vecchia C, Ancelle-Park RA (1995) Trends of AIDS incidence in Europe and the United States. *Soz Praventivmed* **40**: 239–265
- Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, Biggar RJ (2006) Trends in cancer risk among people with AIDS in the United States 1980–2002. *AIDS* **20**: 1645–1654
- Franceschi S, Dal Maso L, Pezzotti P, Polesel J, Braga C, Piselli P, Serraino D, Tagliabue G, Federico M, Ferretti S, De Lisi V, La Rosa F, Conti E, Budroni M, Vicario G, Piffer S, Pannelli F, Giacomini A, Bellu F, Tumino R, Fusco M, Rezza G, for the Cancer and AIDS Registry Linkage Study (2003) Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986–1998. *J Acquir Immune Defic Syndr* **34**: 84–90
- Gulich AE, Li Y, McDonald AM, Correll PK, Law MG, Kaldor JM (2001) Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. *AIDS* **15**: 629–633
- Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S (2002) Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. *Lancet Infect Dis* **2**: 281–292
- Holkmann OC, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD (2007) Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. *HIV Med* **8**: 96–104
- IARC (1997) *IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 70: Epstein-Barr Virus and Kaposi's Sarcoma Herpesvirus/Human Herpesvirus 8*. IARC Press: Lyon
- International Collaboration on HIV and Cancer (2000) Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. *J Natl Cancer Inst* **92**: 1823–1830
- Krown SE, Lee JY, Dittmer DP (2008) More on HIV-associated Kaposi's sarcoma. *N Engl J Med* **358**: 535–536
- Ledergerber B, Telenti A, Egger M, for the Swiss HIV Cohort Study (1999) Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. *BMJ* **319**: 23–24
- Maurer T, Ponte M, Leslie K (2007) HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. *N Engl J Med* **357**: 1352–1353

- Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, Antunes F, Stellbrink HJ, Phillips AN, Lundgren JD (2004) The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. *Cancer* **100**: 2644–2654
- Osmond DH, Buchbinder S, Cheng A, Graves A, Vittinghoff E, Cossen CK, Forghani B, Martin JN (2002) Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. *JAMA* **287**: 221–225
- Polesel J, Clifford GM, Rickenbach M, Dal Maso L, Battegay M, Bouchardy C, Furrer H, Hasse B, Levi F, Probst-Hensch NM, Schmid P, Franceschi S, the Swiss HIV Cohort Study (2008) Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS* **22**: 301–306
- Rezza G, Dorrucchi M, Serraino D, Andreoni M, Giuliani M, Zerboni R, Sarmati L, Colangeli V, Salassa B, Monini P, Ensoli B, Pezzotti P (2000) Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study. *AIDS* **14**: 1647–1653
- Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtou L, Neaton JD, Tambussi G, Abrams DI (2007) Risk of cancers during interrupted antiretroviral therapy in the SMART study. *AIDS* **21**: 1957–1963
- Taffé P, Rickenbach M, Hirschel B, Opravil M, Furrer H, Janin P, Bugnon F, Ledergerber B, Wagsel T, Sudre P (2002) Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. *AIDS* **16**: 747–775